Home
Kailera Therapeutics

Kailera Therapeutics Market Share Analysis for June 2026

Find out about life at Kailera, a clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies for people living with obesity.

Health > Biotechnology and Pharmaceuticals

Domainkailera.com

Year Founded--

Employees51 - 200

Annual Revenue--

Kailera Therapeutics

Kailera Therapeutics (including company regionals)

kailera.com

See more website traffic and engagement information

Total visits to Kailera Therapeutics's top domains

Understand Kailera Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kailera.com12.2K

See more with Sales Intelligence

Avg. visit duration in Kailera Therapeutics's top domains

Analyze Kailera Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kailera.com00:00:22

See more with Sales Intelligence

Avg. pageviews on Kailera Therapeutics's top domains

See how Kailera Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kailera.com2.00

See more with Sales Intelligence

Kailera Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

bioxceltherapeutics.comCompany NameBioXcel TherapeuticsEmployees51 - 200HQUnited States, Connecticut, New HavenAnnual revenue$15M - $25MTotal visits5.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Kailera Therapeutics

These are the website technologies, by industry, used by Kailera Therapeutics top domains

Payment & Currencies (8)

Cart Functionality

Widget (4)

reCAPTCHA

Content Management System (2)

WordPress

Conversion & Analytics (2)

Google Analytics

More Technologies

11

See all

News & Signals from Kailera Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKailera Therapeutics, Inc. hired Kathleen Tregoning as Chief Corporate Affairs Officer on Jun 29th '26.WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) - Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.

NewsKailera Therapeutics, Inc. is developing lead candidate ribupatide injection, a once-weekly on Jun 2nd '26.Kailera is a clinical-stage biotechnology firm focused on obesity care and is advancing four clinical-stage product candidates that leverage GLP-1-based mechanisms, including lead candidate ribupatide injection (KAI-9531), a once-weekly GLP-1/GIP receptor dual agonist currently in global Phase 3 trials.

NewsKailera Therapeutics, Inc. attended event 86th Scientific Sessions on Jun 5th '26.SHANGHAI and WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) - Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the presentation of two abstracts at the 86th Scientific Sessions of the American Diabetes Association (ADA), taking place June 5-8, 2026 in New Orleans, Louisiana.